Daily archives "October 10, 2017"

NuoDB Cloud Database Improving Companies’ Performance

NuoDB is an advanced elastic SQL database for cloud applications and container-based environments. NuoDB helps to adjust the cloud database performance and size according to the demand without risking data integrity, standard-based SQL or transactional consistency. NuoDB was founded in 2008 as NimbusDB by Barry S. Morris and Jim Starkey with its headquarters in Cambridge, Massachusetts.

Moreover, NuoDB can support active to active deployment both read and write, across hybrid or multi-cloud database environments and even up to three data centers improving customer performance. Cloud database is no longer traditional with NuoDB on board as transactional consistency has improved.

Other than being productive, NuoDB provides clients with advantages like elastic scalability, transactional consistency, flexibility, continuous availability and data durability. NuoDB cloud database uses a tiered method to operate. Multiple tiers of storage managers(SM) and transaction engines (TE) run on the same platform.

TEs have nodes which can be added or removed depending on the transaction volume. Therefore with this cloud database, you donot need to replace hardware as it can expand its databases by increasing the servers. NuoDB can operate over 1 million transactions per second. Cloud database services by NuoDB are used by many companies like UAE Exchange, Kodiak, Dassault Systems and Alfa Systems.

Clay Siegall Believe in the Power of Collaboration to Improve Cancer Treatment Options

Inspirey published the interview, “Dr. Clay Siegall—CEO, Seattle Genetics” to show the inspiration of the targeted cancer therapy hero. Dr. Siegall is the co-founder, President, and CEO of Seattle Genetics. Seattle Genetics is a biotech company that creates targeted cancer therapy drugs that use antibodies and cell-killing agents to target tumors. The drugs are particularly focused in treating Hodgkin lymphoma and relapsed systemic anaplastic lymphoma.

He believes a powerful aspect of the business is through collaboration with other industry leaders, particularly oncology drug development companies. Through the collaboration, Seattle Genetics’ technology allows them to become more innovative with new approaches to help other patients.

Through the strong leadership of Dr. Clay Siegall, Seattle Genetics has grown into one of the leaders in the cancer research niche. They have continued to expand their list of drugs and have the first FDA approved ADC. Dr. Siegall seeks to end the reign of the older cancer treatment options like the systemic chemotherapy.

In fact, the dire effects of chemotherapy was part of the inspiration that led Dr. Siegall to starting the company in the first place. He watched a family member go through cancer treatment with chemotherapy, which had brutal side effects of severe anemia which nearly led to the family member’s death. He saw that the only options available were chemotherapy and invasive surgeries and he realized he needed to change that.

Yet, he had been fascinated with diseases and the ability of technology and medicine to restore health since studying zoology at the University of Maryland. Later, he went on to gain his doctorate in genetics from George Washington University.

Dr. Siegall has a long career in the research field. Prior to starting Seattle Genetics, Dr. Siegall was the senior researcher at Bristol Myers Squibb Pharmaceutical Research Institute. He also worked with the National Cancer Institute and is currently on the Board of Directors for Alder BioPharmaceuticals.

Dr. Siegal has also published more than 70 papers and has 15 patents. As the leader in the capital-raising activites, Dr. Siegall was able to gain $675 million of financing for Seattle Genetics. They have developed a diverse array of drugs in the pipeline, with the mainstay of ADCETRIS which was FDA approved in 2011.

Leveraging Public-Private Partnerships To Improve Access To Basic Services In Brazil

Government grants can accelerate access to clean water and sanitation services. The Brazilian government recently announced concessions in collaboration with the National Bank for Economic and Social Development. Stakeholders such as Edison Carlos of Tata Brazil welcomed the move. He stated that you could expect better services from the improved management of resources.

Felipe Montoro Jens, an infrastructure specialist, also noted that there would be decreased levels of waste. State agencies are in charge of water and sanitation services. They can improve their service delivery by collaborating with the private sector. Each has their strong points, which can complement the other to achieve efficiency. The bank will create custom plans for the implementation based on the unique needs of each location.

Water loss was identified as one of the leading causes of loss of revenue by the state agencies. Water that does not get to the intended customer cannot be billed. The private sector has access to larger pools of funding and the latest technology. This makes them ideal partners in the development of sewage networks and sanitation facilities. The technology can also be used to reduce water waste and consequent loss of revenue.

The success of a state agency can be measured by the level of penetration of their services.

Felipe Montoro Jens is a management and finance executive as well as an influential business leader. He has extensive experience in the Brazilian corporate sector.

He has also held c-level management positions in countries such as the UK and Singapore. This includes positions in project management, structured and international finance, and auditing.

He is adept at helping agencies achieve efficiency and improve their bottom line. He attended Getulio Vargas Foundation where he obtained a business administration degree. He then went for further studies at the Thunderbird School of Global Management, a part of Arizona State University.